|
業務類別
|
Biotechnology |
|
業務概覽
|
Fractyl Health Inc is a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D). Its Revita and Rejuva candidates are designed to target root causes of metabolic diseases, allowing the company to advance metabolic disease treatment from chronic management towards prevention and reversion of the disease. The Revita DMR System (Revita), its lead product candidate, is based on its insights surrounding the potential role of the gut in obesity. |
| 公司地址
| 3 Van de Graaff Drive, Suite 200, Burlington, MA, USA, 01803 |
| 電話號碼
| +1 781 902-8800 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.fractyl.com |
| 員工數量
| 100 |
| Mr. Jay D. Caplan |
President and Chief Product Officer |
美元 475.00K |
24/04/2026 |
| Ms. Lara Smith-Weber |
Chief Financial Officer and Principal Accounting Officer |
-- |
06/01/2026 |
| Dr. Harith Rajagopalan, M.D.,PhD |
Chief Executive Officer and Director |
美元 610.00K |
24/04/2026 |
| Ms. Sarah Toomey |
General Counsel and Corporate Secretary |
美元 445.00K |
24/04/2026 |
|
|
| Senator William W. Bradley |
Independent Director |
24/04/2026 |
| Dr. Clive A. Meanwell, M.B.,M.D. |
Independent Director |
24/04/2026 |
| Mr. Marc Elia |
Independent Director |
24/04/2026 |
| Mr. Ajay Royan |
Chairman of the Board |
24/04/2026 |
| Dr. Harith Rajagopalan, M.D.,PhD |
Chief Executive Officer and Director |
24/04/2026 |
| Ms. Kelly Ann Barnes |
Independent Director |
24/04/2026 |
| Mr. Samuel Conaway |
Independent Director |
24/04/2026 |
| Mr. Ian Sheffield |
Independent Director |
24/04/2026 |
| Dr. Christopher Thompson, M. Sc.,M.D. |
Independent Director |
24/04/2026 |
|
|
|
|
